02597nam a2200385 i 45000010008000000030008000080050017000160060019000330070007000520080041000590200033001000350017001330390012001500400036001620500024001980900025002222450121002472640037003682640011004053000023004163360021004393370023004603380032004835040051005155050618005665200611011845960007017956500041018026500022018437000033018658560110018989490014020089260105020227580084021276748930FlBoTFG20141121161956.0m|||||o||d||||||||cr||||141121t20152015fluad   ob    001 0 eng d  a9781466579996 (e-book : PDF)  aocn896599212  aexclude  aFlBoTFGbengcFlBoTFGerdadAEU 4aHD9665.5b.R45 2015  aInternet AccessbAEU00aRe-inventing drug development /cedited by Jeffrey S. Handen, PhD, Medidata Solutions, Inc. New York, New York, USA. 1aBoca Raton :bCRC Press,c[2015] 4cÂ©2015  a1 online resource.  atext2rdacontent  acomputer2rdamedia  aonline resource2rdacarrier  aIncludes bibliographical references and index.0 aRedefining innovation / Jeffrey S. Handen -- Collaborations of the future / Melinda S. Shockley -- Portfolio management : selecting the right "set of projects" to meet product development goals / Arun Kejariwal -- Funding and resourcing clinical development / Michael A. Martorelli -- Emerging role of patients in clinical research / Michael S. Katz -- Innovative organizations : viewpoints of organizational scholars and practitioners / Lindsey Kotrba, Ia Ko and Daniel R. Denison -- Moving toward personalized medicine : how to transform product development / Michele Pontinen, Jian Wang and Christopher Bouton.  a"The biopharmaceutical industry has entered an era of unprecedented change and challenge, characterized by increasing pricing pressures, rising rates of attrition in the product development lifecycle, and decreasing scientific innovation. The most successful products are losing patent protection, and pipelines have been unable to fill the gap. This book explores the evolving definition of innovation in therapeutic product development and begins to examine its effects on and implications to the life sciences R&D industry vis-a-vis collaboration, communication, and integration"--Provided by publisher.  a44 0aPharmaceutical industryxManagement. 0aDrugsxMarketing.1 aHanden, Jeffrey S.,eeditor.403University of Alberta Accessuhttp://marc.crcnetbase.com/isbn/9781466579996z(Unlimited Concurrent Users)  hUAINzCRC  aInternet AccesswLCc1i6748930-1001lINTERNETmUAINTERNETrYsYtE-RESOURCEu12/2/2014xE-BOOKzCRC01ahttp://id.loc.gov/authorities/names/n2004009674bhttp://viaf.org/viaf/269864827